FORTUNE -- Sometimes if it walks like a duck and talks like a duck, it's actually a different animal. That seems to be the lesson from yesterday's news that Valeant Pharmaceuticals (VRX) and activist investor Bill Ackman are partnering on a $50 billion takeover offer for Botox maker Allergan Inc. (AGN), after Ackman secretly acquired nearly a 10% stake in Allergan on Valeant's behalf. The whole thing feels like a classic example of insider trading, except that it most likely isn't.
As my colleague Stephen Gandel reported, Ackman didn't originally have any grand plans to help acquire Allergan. He wanted a stake in Valeant. But when Ackman called company management in early February, he learned thatValeant was eager to acquire Allergan (it was rebuffed last year). So he helped come up with a strategy for getting the combination to work. In short, he would buy up shares of Allergan -- albeit not enough to trigger any HSR disclosures with the Federal Trade Commission -- and then pledge to vote those shares in favor of the eventual acquisition offer (plus make an additional investment).
Or, put more bluntly, Ackman traded on non-public material information.
The reason it apparently isn't insider trading is twofold: First, there was no breach of fiduciary duty to the holder of the confidential information (Valeant). After all, Valeant was the one that volunteered its plans to Ackman, and encouraged him to trade on it. Second, Ackman disclosed the Valeant relationship via a 13D filing with the SEC, which is required after acquiring a 5% stake in a company – even though the current waiting period rules actually let him accumulate around a 9.7% stake by the time the 13D was actually filed.
In the past 24 hours I've heard some suggestions that this deal could become problematic for private equity, if corporations using activists as Trojan horses becomes commonplace. Here's the argument: Strategics already have an advantage over private equity in that their cash is cheaper (even in today's frothy credit environment). Now they'd have an additional advantage in competitive situations, by basically baking in a large shareholder voting on their behalf. At worst, the PE firm would pay a premium and the corporation/activist would receive a profitable return on their investment.
My gut take is that private equity is unlikely to feel any sting here. For starters, PE-sponsored take-privates have been losing popularity. This year in the U.S., for example, there only have been a small handful of deals valued at just $3.12 billion in aggregate, according to Pitchbook. And there have been fewer than 50 such transactions for the past five years (last year's total dollar volume was $55 billion if you include Dell but remove Heinz).
Second, it's hard to imagine that too many corporations are really going to want folks like Ackman within their henhouses. Third, we don't even know if their strategy is going to work out for Valeant. Allergan has not yet formally responded, except to say that it's examining the offer.
Certainly something to watch, but not anything to keep PE pros up at night.
Sign up for Dan Primack's daily email newsletter on deals and deal-makers: GetTermSheet.com
In fact, the deal has two activist investor backers, not one.
FORTUNE -- The proposed acquisition of Botox maker Allergan by eyecare pharmaceutical company Valeant appears to be driven by activist hedge fund investor Bill Ackman, of Herbalife fame.
But, in fact, the deal has two activist-investor backers, not one.
Jeff Ubben of ValueAct says he has been pushing for the acquisition for almost a year, and he backs it now. "It's a MOREStephen Gandel, senior editor - Apr 22, 2014 1:24 PM ET
The differing tactics of two activist investors reveal boards with a lack of focus on corporate governance.
By Paul Hodgson
FORTUNE -- Hedge fund activists often have very different strategies from each other, and very different opinions about a company's fortunes. Take William Ackman's shorting of Herbalife (HLF), while at the same time George Soros, Daniel Loeb, and Carl Icahn all took long positions in the stock. But one element underlies most if not MOREMar 31, 2014 5:00 AM ET
Despite the U.S. government's investigation of Herbalife, Pershing Square could lose its bet.
By Sanjay Sanghoee
FORTUNE -- Herbalife (HLF) can't seem to get a break. Last week, the Federal Trade Commission announced it had opened an official inquiry into the $6 billion nutritional supplement company -- a move that surely gave Bill Ackman's Pershing Square fund a much-needed shot in the arm. The New York City-based hedge fund has placed a virtual bounty on Herbalife's head MOREMar 17, 2014 5:00 AM ET
The primary regulator in charge of policing multi-level marketing frauds has only brought three new cases in the past 13 years.
FORTUNE -- Bill Ackman's campaign to prove that diet shake company Herbalife is operating a pyramid scheme has finally paid a dividend.
On Wednesday, Herbalife disclosed that it was under investigation by the Federal Trade Commission. The FTC later confirmed the news. Shares of Herbalife (HLF) have fallen 12% since the MOREStephen Gandel, senior editor - Mar 13, 2014 1:39 PM ET
It may seem awkward, but is there anything actually wrong with a hedge fund manager bankrolling an all-out assault on a company?
Correction: March 10, 4:45 PM.
FORTUNE -- Bill Ackman really, really wants to prove that Herbalife is a fraud. That's not new. What's new is the lengths he is apparently going to to convince everyone, particularly regulators, that he is right.
On Monday, the New York Times detailed those efforts in MOREStephen Gandel, senior editor - Mar 10, 2014 2:59 PM ET
J.C. Penney needs to seriously rethink its business model and it needs the space to execute on a new strategy. That cannot happen in the frenetic public markets.
By Sanjay Sanghoee
FORTUNE -- Shares of embattled retailer J.C. Penney surged this week on news that its cash levels at year-end will be better than expected. That is certainly good news for a company that has had nothing but problems lately. MOREOct 9, 2013 1:23 PM ET
Famed hedge fund manager Leon Cooperman blasts fellow investor Bill Ackman on his Herbalife bet.
FORTUNE -- The pile on continues.
Yet another legendary investor is calling out Bill Ackman for his controversial bet against Herbalife (HLF). Late last year, Ackman made a public presentation calling the nutritional supplements company a pyramid scheme. He also said he had bet $1 billion against the company.
Leon Cooperman, who runs hedge fund firm Omega Advisors, MOREStephen Gandel, senior editor - May 5, 2013 10:47 AM ET
Funds have underperformed at a time when they are drawing more and more money from middle class retirement accounts.Stephen Gandel, senior editor - Apr 19, 2013 11:51 AM ET
Why this boutique investment bank matters on Wall Street -- and beyond.
FORTUNE -- As big investment banks wrestle with tarnished reputations and accusations of conflicts of interest, the allure of Wall Street boutiques only grows. They offer advice -- nothing else -- and have none of the other operations, such as trading, that breed conflicts. One firm little known outside of financial circles, Centerview Partners, has become a key player. MOREShawn Tully, senior editor-at-large - Aug 27, 2012 5:00 AM ET
|Many low-wage workers not protected by minimum wage|
|HBO shows coming to Amazon ... not Netflix|
|Students cry foul over athletes unionizing|
|Delinquent IRS employees paid bonuses by the agency|
|Is capitalism driving itself out of business?|